2. Academic Validation
  3. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916

A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916

  • Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. doi: 10.1517/13543776.2011.622750.
Peter Norman 1
Affiliations

Affiliation

  • 1 Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. petrosn@bigfoot.com
PMID: 21936726 DOI: 10.1517/13543776.2011.622750
Abstract

This application claims the dual CCR2/CCR5 Antagonist (S)-1-[(1S,2R,4R)-4-isopropyl(methyl)amino)-2-propylcyclohexyl]-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one, crystalline form N-1, a process for its preparation and therapeutic uses of it. The compound is shown to be a potent, well-absorbed, drug with a good duration of action. It shows better properties than similar compounds previously claimed by Bristol-Myers Squibb and appears to be a clinical development candidate.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z